REFERENCES
- Rubinstein L J. Pathological features of optic nerve and chiasmatic gliomas. Neurofibromatosis. 1988; 1: 152–158
- Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1. J Pediatr. 1994; 125: 63–66
- Zeid J L, Charrow J, Sandu M, Goldman S, Listernik R. Orbital optic nerve gliomas in children with neurofibromatosis type 1. JAAPOS. 2006; 10: 534–539
- National Institutes of Health. Neurofibromatosis. National Institutes of Health Consensus Development Conference Statement. NIH, Bethesda, MD 1987; 6
- Listernick R, Charrow J. Neurofibromatosis type 1 in childhood. J Pediatr. 1990; 116: 845–853
- Parsa C F, Hoyt C S, Lesser R L, Weinstein J M, et al. Spontaneous regression of optic gliomas—Thirteen cases documented by serial neuroimaging. Arch Ophthalmol. 2001; 119: 516–529
- Listernick R, Charrow J, Tomita T, Goldman S. Carboplatin therapy for optic pathways tumors in children with neurofibromatosis type-1. J Neurooncol. 1999; 45: 185–190
- Parsa C F. Givrad S: Pilocytic astrocytomas as hamartomas: Implications for treatment. Br J Ophthalmol 2008; 92: 3–6
- Packer R J, Ater J, Allen J. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997; 86: 747–754